Vasoactive intestinal peptide (VIP), which is present with acetylcholine in parasympathetic nerve fibers, may have important regulatory functions in mucous membranes. The potential roles for VIP in human nasal mucosa were studied using an integrated approach. The VIP content of human nasal mucosa was determined to be 2.84 +/-0.47 pmol/g wet weight (n = 8) by RIA. VIP-immunoreactive nerve fibers were found to be most concentrated in submucosal glands adjacent to serous and mucous cells. 125I-VIP binding sites were located on submucosal glands, epithelial cells, and arterioles. In short-term explant culture, VIP stimulated lactoferrin release from serous cells but did not stimulate [3H]glucosaminelabeled respiratory glycoconjugate secretion. Methacholine was more potent than VIP, and methacholine stimulated both lactoferrin and respiratory glycoconjugate release. The addition of VIP plus methacholine to explants resulted in additive increases in lactoferrin release. Based upon the autoradiographic distribution of 125I-VIP binding sites and the effects on explants, VIP derived from parasympathetic nerve fibers may function in the regulation of serous cell secretion in human nasal mucosa. VIP may also participate in the regulation of vasomotor tone. Invest. 1990. 86:825-831.)
Introduction
Vasoactive intestinal peptide (VIP;' 28 amino acid residues; 1) is a neurotransmitter in postganglionic parasympathetic neurons. Preganglionic parasympathetic nerves of the nasal mucosa originate in the superior salivatory nucleus of the seventh cranial nerve, pass through the Vidian nerve, and synapse with postganglionic cell bodies in the sphenopalatine ganglion (2) (3) (4) . Postganglionic cholinergic neurons contain VIP, pep- tide with histidine at the NH2 terminus and methionine at the COOH terminus (PHM), and both choline acetyl transferase and acetylcholinesterase, which indicate the presence of acetylcholine (5-7). The neurons enter the mucosa via the poste-rior nasal nerves and innervate submucosal glands, arterioles, and venules (3, 4, 7) . Stimulation of parasympathetic neurons leads to the release of acetylcholine, which acts upon muscarinic receptors on submucosal glands (8) and possibly vessels (9, 10) .
In humans, stimulation of submucosal glands by exogenous methacholine (8) or central reflexes (1 1) leads to secretion of such mucous cell products as mucous glycoconjugates, and serous cell products such as lactoferrin, lysozyme, secretory component, and secretory IgA (8, (11) (12) (13) . Stimulation of vessels by either cholinergic agonists or central parasympathetic reflexes has been suggested to cause vasodilation (9, 10, 14, 15) and may contribute to the secretion ofplasma products such as albumin and IgG. Parasympathetic efferent reflexes may be initiated by afferent sensory nerve stimulation (1 1, 13), or by "short circuit" stimulation of postganglionic parasympathetic cell bodies by nociceptive, substance P-containing trigeminal neurons (16) . In addition, electrical stimulation ofthe sphenopalatine ganglion leads to atropine inhibitable nasal secretion and atropine-resistant vasodilation (3) .
Since VIP is released along with acetylcholine by parasympathetic nerves, VIP may play an important role in regulating nasal responses. However, there is little understanding of the functions of VIP in the nasal mucosa. Therefore, the concentration of VIP in human nasal mucosa was measured by RIA, the locations of VIP-immunoreactive nerve fibers were determined by immunohistochemistry, the distribution of '251I-VIP binding sites was determined by autoradiography, and the effects on the secretion of mucous and serous cell products from submucosal glands were determined by exposing human nasal mucosal fragments to VIP in short term explant culture. Based upon this integrated approach, inferences were made about the role of VIP in the regulation of vascular and glandular responses of human nasal mucosa.
Methods
Tissue handling. Human inferior turbinates were obtained at the time of surgery from 35 patients with nasal obstructive syndromes. No patient had had a recent infection. At the time ofsurgery, 2% tetracaine HCl and 0.25% phenylephrine HCl were applied topically on nasal packs. The turbinates were injected with 2-4 ml of 1% lidocaine with 1:100,000 epinephrine. An incision was made from the lateral wall of the inferior turbinate at the level of the infundibulum through the inferior conchal bone, and then inferiorly along the medial aspect of that bone. The medial flap of turbinate that remained was wrapped superiorly and laterally to close the wound. Within 20 min of surgical excision, the nasal mucosa was dissected from the inferior conchal bone. Mucosal specimens for autoradiography were frozen in 2-methyl-butane on dry ice for 20 s, then stored at -700C. Specimens for explant culture were placed in L15 media (Biofluids, Rockville, MD) supplemented with 100 ,ug/ml penicillin, 100 ;g/ml streptomycin, and 0.5 gg/ml amphotericin for transport to the laboratory. (1 14M pumps, 421 controller, and 164 detector; Beckman Instruments, Inc., Fullerton, CA) using a C-18 reverse-phase column (ODS Ultrasphere, 4.6 X 25 cm, 5 Jim pore size, Beckman Instruments, Inc.). Samples were eluted 5 min after injection using 45-min runs and a linear gradient of 0-90% eluent B (0.12% trifluoroacetic acid in acetonitrile) in eluent A (22) . Synthetic VIP (Peninsula Laboratories) was used to standardize the column. Frac- tions were collected at 1-min intervals, frozen, lyophilized, and reconstituted in RIA buffer. The VIP content of each fraction was determined by RIA.
Indirect immunohistochemistry. 6-Mtm-thick paraffin sections were sequentially placed in xylene, graded alcohols, distilled water, PBS, and PBS with 1% nonimmune goat serum (11, 13) . Sections were incubated with rabbit antisera (1:1,000) to VIP (Peninsula Laboratories) or with nonimmune rabbit serum for 18 or 44 h at 4VC. The slides were washed in PBS, reblocked with 1% nonimmune goat serum in PBS for 3 min at room temperature, and then 1:40 colloidal gold-labeled goat anti-rabbit gamma globulin (Auroprobe; Janssen Pharmaceuticals Piscataway, NJ) was added for 60 min at room temperature. After being washed three times in PBS for 5 min each and three times in distilled water for 3 min each at room temperature, silver enhancing solution (IntenSE; Janssen Pharmaceuticals) was added and the development of the stained structures was monitored by light microscopy. The slides were washed in distilled water, dehydrated in graded alcohols, and coverslips applied with Permount (Sigma Chemical Co.).
Autoradiography. VIP-immunoreactive material was identified readily in tissue fixed by microwave irradiation. Microwave fixation allowed rapid tissue processing and excellent preservation of tissue histology, and improved the identification of immunoreactive nerve fibers when compared with other fixation techniques ( 17) . This may reflect the rapidity of tissue fixation by microwave irradiation.
Staining sections with nuclear fast red (Sigma Chemical Co.) allowed tissue definition which did not obscure nerve fibers. Other stains obscured detection ofimmunoreactive VIP nerves which could otherwise be seen in unstained sections.
VIP immunoreactive nerve fibers were most frequently encountered in submucosal glands (Fig. 1) . The fibers were often in direct contact with acinar cells. There was apparent contact with both serous and mucous cells, and with the myoepithelial cells that surround each acinus. VIP fibers were seen in nerve bundles. Some VIP nerve fibers were also detected in the walls of arterial and venous vessels. More fibers were seen in glands than vessels. No fibers were found in the epithelium.
Autoradiography. '25I-VIP binding sites on the epithelium and submucosal glands of human nasal mucosa were detected as deposits of silver grains using darkfield microscopy ( Fig. 2) . (Fig. 3) Since VIP and acetylcholine may be simultaneously released from parasympathetic nerves, the effects of combinations of methacholine and VIP were studied. The addition of VIP to 1 uM methacholine did not stimulate glycoconjugate release or augment the release of lactoferrin. The addition of VIP to 10 1AM methacholine did not affect glycoconjugate release. Lactoferrin release was increased in additive but not VIP-containing neurons also contain a closely related peptide: PHM (37, 38). Although VIP, PHM, and acetylcholine are all present in the peripheral neurosecretory varicosities of postganglionic parasympathetic neurons (39) , the amounts of each released during neural transmission appears to depend upon the nerve impulse frequency (39) . At low rates, acetylcholine is selectively released. At high rates, acetylcholine together with VIP and PHM are released. VIP may augment the postsynaptic acetylcholine-induced secretory response in glands (e.g., cat salivary glands, reference 40), but may also have presynaptic inhibitory effects which could act to limit neuropeptide release. This mechanism would conserve the amount of stored peptides since there are no re-uptake mechanisms, and VIP and PHM can only be resupplied by axonal transport from the cell body (37, 39). This principle may be very important in understanding the physiology ofparasympathetic neurons.
VIP stimulates many aspects of exocrine function and increases the content of chloride in intestinal and bronchial secretions, and pancreatic secretion of bicarbonate, water, and macromolecules (33) . In respiratory tissues, however, the effects of VIP on glands have been inconsistent. Tracheal tissues from ferret (41, 42) and dog (43) release modest amounts of respiratory glycoconjugates ("mucus") in response to VIP. VIP induces serous cell exocytosis from ferret tracheal explants (42) . Feline tracheal explants do not respond to VIP (44) . However, isolated feline submucosal glands do respond (44) , and VIP augments the secretory responses of methacholine (44) and other secretagogues (45) . In humans, incubation of tracheal explants with 0.2-2,000 nM VIP inhibited [3H]glycoconjugate release from normal subjects, but had no effect upon explants from subjects with chronic bronchitis (46) .
The present explant results indicate that VIP stimulated lactoferrin secretion from serous cells. VIP was less potent than methacholine and did not significantly augment muscarinic receptor-mediated stimulation of lactoferrin secretion.
VIP did not stimulate [3H]glucosamine-labeled respiratory glycoconjugate release and did not affect methacholine-induced secretion. The release of lactoferrin was much more responsive than [3H]glycoconjugate release. Either serous cells were more sensitive to methacholine than glycoconjugatecontaining cells, or lactoferrin was a more sensitive marker of submucosal gland secretion than glycoconjugates. Therefore, VIP augments the effects ofcholinergic stimulation by causing selective enrichment ofserous cell products in nasal secretions. The activation of VIP receptors on serous cells of submucosal glands represents an additional component which must be considered when studying parasympathetic reflexes in human upper respiratory tract (1 1).
'25I-VIP binding sites were also found on vessels. VIP induces dilation of human submandibular arteries in vitro (15) and feline nasal vessels in vivo (47, 48) . VIP augments the cutaneous plasma extravasation that can be induced by substance P (49) .
Alterations of VIP metabolism may contribute to several clinical syndromes. Increased VIP immunohistochemical staining in nasal mucosa has been reported in patients with an allergic diathesis and symptoms of paroxysmal nasal obstruction (50) . Increased release of VIP and other neurotransmitters by the parasympathetic route could contribute to the chronic vascular congestion and hypersecretion characteristic of some obstructive nasal syndromes. In contrast, VIP-immunoreactive nerve fibers may be absent from bronchial walls in patients who die of status asthmaticus (5 1). These asthmatic patients were also reported to have increased relative densities of substance P-immunoreactive nerve fibers in their bronchial mucosa (52) . These findings suggest that abnormalities of neuropeptide containing nerves could contribute to the pathogenesis of respiratory diseases. Prospective studies with carefully defined patient groups and appropriate controls are required to implicate neuropeptides in specific disease states.
These observations indicate that VIP is present in human nasal mucosa and that VIP-immunoreactive neurons innervate submucosal glands and vessels. VIP binding sites are present on the epithelium, submucosal glands, and the walls of arterioles. VIP stimulated lactoferrin release from human nasal mucosal fragments. Since serous cell products include specific and nonspecific antimicrobial factors, this selective response could be an important regulator of mucosal host defense mechanisms.
